Le Lézard
Classified in: Health
Subjects: LAW, SCZ

National Trial Firm Successfully Litigates the Disallowance of Over $6 Million in Senior Claims Against Bankrupt Hosiptal

LOS ANGELES, April 17, 2019 /PRNewswire-PRWeb/ -- Bienert | Katzman PC ("BK") has successfully litigated the rejection of over 95% of the senior claims asserted against bankrupt Gardens Regional Hospital and Medical Center, Inc. ("Gardens") on behalf of its client, Michael R. Lane, the Liquidating Trustee of Gardens. The disallowed senior claims totaled over $6 million. The U.S. Bankruptcy Court disallowed the claims on a summary basis, without requiring a trial.

On February 4, 2019, the Liquidating Trustee filed his multiple objections to over $6 million in priority claims against Gardens, which are a high-ranking type of claim that is entitled to be paid first in a bankruptcy case and, to the extent there are sufficient assets, is paid in full. Unless these claims were disallowed, there would likely be no recovery for Gardens' other creditors. Therefore, it was critical to obtain the disallowance of the claims.

On March 6, 2019, the U.S. Bankruptcy Court overruled all of the creditors' oppositions and sustained every one of the claim objections. This reduced the administrative expense claims against Gardens by over 95%, and cleared the path to allow other creditors of Gardens to obtain a recovery on their claims. Notably, BK successfully litigated: the complete disallowance on the merits of a $5 million fraud claim arising out of a spinal surgery; the complete disallowance of contract claims on the basis that the claimants failed to establish value to Gardens, regardless of what they might be entitled to under their contracts; and the complete disallowance of contract claims because the claims arose under the contract after it was rejected in the bankruptcy case by Gardens.

BK founding partner Steven Jay Katzman, partner David M. Guess and Anthony Bisconti represent the Liquidating Trustee in the Gardens case, together with Andrew Sherman and Boris Mankovetskiy of Sills Cummis & Gross P.C..

Bienert | Katzman PC (BK) is a San Clemente-based trial firm that consists of former federal and state prosecutors, federal public defenders, former judicial clerks, and large firm trained attorneys. Its lawyers collectively have conducted hundreds of jury and court trials. The result in this case is the latest in a string of outstanding results for the firm's clients, including both multi-million dollar verdicts and settlements and major defense victories. BK combines nationally-recognized expertise and relentless creativity with a boutique legal setting that ensures personalized attention to every client and case.

** In re Gardens Regional Hospital and Medical Center, Inc., Case No. 2:16-bk-17463-ER (United States Bankruptcy Court for the Central District of California, Los Angeles Division)


SOURCE Bienert | Katzman PC

These press releases may also interest you

at 05:00
Governments across the country have been denying Canadians access to vital information about the novel coronavirus and their responses to it, while failing to protect whistleblowers who could expose threats to public health ? whether they are in...

at 04:56
kneat.com, inc. ("Kneat"), announces that the Company will release its Financial Results for the quarter ended March 31, 2020 after TSX market close on Wednesday 27 May 2020. ...

at 04:35
The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a new report by Grand View Research, Inc. Allogenic tissue transplant method efficiently addresses challenges and...

at 04:23
Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The...

at 04:00
As governments in many countries are easing lockdown restrictions, fitness facilities are getting ready to re-open and welcome back customers. After the pandemic, health has certainly risen to the top of the list of consumers' personal priorities,...

at 03:30
The "Global Molecular Point of Care (mPOC) Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The molecular point of care (mPOC) devices market is poised to grow by $ 816.62 million during 2020-2024 progressing at...

News published on 17 april 2019 at 08:55 and distributed by: